Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the pharmaceutical giant is one of the ...

The latest declines in Eli Lilly's stock price occurred in response to management's presentation at the annual JPMorgan ... The Motley Fool Stock Advisor analyst team just identified what they believe ...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good ...

In a recent press release, Eli Lilly's management said that the U.S. incretin ... The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in lower-than-expected revenue for the company's famous weight management drug ...